The estimated Net Worth of Richard Straube is at least $322 Thousand dollars as of 18 May 2022. Dr Straube owns over 8,000 units of Soligenix Inc stock worth over $27,520 and over the last 11 years he sold SNGX stock worth over $0. In addition, he makes $294,508 as Sr. VP & Chief Medical Officer at Soligenix Inc.
Dr has made over 1 trades of the Soligenix Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 8,000 units of SNGX stock worth $4,000 on 18 May 2022.
The largest trade he's ever made was buying 8,000 units of Soligenix Inc stock on 18 May 2022 worth over $4,000. On average, Dr trades about 615 units every 0 days since 2014. As of 18 May 2022 he still owns at least 8,000 units of Soligenix Inc stock.
You can see the complete history of Dr Straube stock trades at the bottom of the page.
Dr. Richard C. Straube M.D., MSc. is the Sr. VP & Chief Medical Officer at Soligenix Inc.
As the Sr. VP & Chief Medical Officer of Soligenix Inc, the total compensation of Dr MSc at Soligenix Inc is $294,508. There are 4 executives at Soligenix Inc getting paid more, with Dr. Christopher J. Schaber Ph.D. having the highest compensation of $810,303.
Dr MSc is 69, he's been the Sr. VP & Chief Medical Officer of Soligenix Inc since . There are 3 older and 9 younger executives at Soligenix Inc. The oldest executive at Soligenix Inc is Richard L. Dunning, 75, who is the Exec. Officer.
Richard's mailing address filed with the SEC is C/O SOLIGENIX, INC., 29 EMMONS DRIVE, SUITE B-10, PRINCETON, NJ, 08540.
Over the last 15 years, insiders at Soligenix Inc have traded over $502,220 worth of Soligenix Inc stock and bought 775,279 units worth $1,096,136 . The most active insiders traders include Randal Jintrexon Corp Kirk, Jerome B Zeldis, and Spacavazza Paolo Leadiant B.... On average, Soligenix Inc executives and independent directors trade stock every 115 days with the average trade being worth of $91,349. The most recent stock trade was executed by Richard Straube on 18 May 2022, trading 8,000 units of SNGX stock currently worth $4,000.
soligenix, inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous t-cell lymphoma, oral mucositis, pediatric crohn's disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.
Soligenix Inc executives and other stock owners filed with the SEC include: